Xiaohui Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaohui Hu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Degui Wang
Department of Anatomy and Histology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
1 shared publication - Peng Xia
School of Basic Medical Sciences Lanzhou University Lanzhou Gansu China
1 shared publication Pengfei Ji
School of Basic Medical Sciences Lanzhou University Lanzhou Gansu China
1 shared publicationRong Shen
School of Basic Medical Sciences Lanzhou University Lanzhou Gansu China
1 shared publicationSi Shuang
School of Basic Medical Sciences Lanzhou University Lanzhou Gansu China
1 shared publicationWenhao Dong
School of Basic Medical Sciences Lanzhou University Lanzhou Gansu China
1 shared publication
Latest Publications
- 15 December 2025
- Published by Wiley in International Journal of Immunogenetics
- Vol. 53 (2) , 98-117
Research Advances in the Physiological and Pathological Function of MYH9 and NMIIA
The MYH9 gene encodes the heavy chain of non‐muscle myosin IIA (NMIIA), which converts chemical energy into mechanical energy and provides power for the contraction of the actin cytoskeleton. This is necessary for many important physiological processes such as cell morphology maintenance, migration, adhesion, division and individual development. Patients with autosomal dominant genetic diseases caused by MYH9 mutation show macrothrombocytopenia and complications such as renal failure, deafness and cataracts. However, in recent years, more and more studies have found that the activity of NMIIA is also related to various other diseases, including cancer, neurological diseases and infectious disorders. This article introduces the characteristics of myosin superfamily members and systematically reviews the structure, regulation and physiological functions of MYH9 and NMIIA, as well as MYH9 ‐related disorders ( MYH9 ‐RD) caused by MYH9 mutations, focusing on the role of NMIIA in the pathogenesis of various cancers, and summarizes the therapeutic mechanisms of its targeted drugs. Besides, the effects of NMIIA in neurological diseases and infectious diseases are discussed to provide a comprehensive theoretical basis and insights for MYH9 and NMIIA as a therapeutic target for multiple diseases.
- 15 December 2025
- Published by Wiley in International Journal of Immunogenetics
- Vol. 53 (2) , 98-117
Research Advances in the Physiological and Pathological Function of MYH9 and NMIIA
The MYH9 gene encodes the heavy chain of non‐muscle myosin IIA (NMIIA), which converts chemical energy into mechanical energy and provides power for the contraction of the actin cytoskeleton. This is necessary for many important physiological processes such as cell morphology maintenance, migration, adhesion, division and individual development. Patients with autosomal dominant genetic diseases caused by MYH9 mutation show macrothrombocytopenia and complications such as renal failure, deafness and cataracts. However, in recent years, more and more studies have found that the activity of NMIIA is also related to various other diseases, including cancer, neurological diseases and infectious disorders. This article introduces the characteristics of myosin superfamily members and systematically reviews the structure, regulation and physiological functions of MYH9 and NMIIA, as well as MYH9 ‐related disorders ( MYH9 ‐RD) caused by MYH9 mutations, focusing on the role of NMIIA in the pathogenesis of various cancers, and summarizes the therapeutic mechanisms of its targeted drugs. Besides, the effects of NMIIA in neurological diseases and infectious diseases are discussed to provide a comprehensive theoretical basis and insights for MYH9 and NMIIA as a therapeutic target for multiple diseases.